Royalty and Commercial Payment Purchase Agreements (Tables)

6 Months Ended

Jun. 30, 2023

Royalty and Commercial Payment Purchase Agreements

Summary of royalty and commercial payment receivable activities

The following table summarizes the royalty and commercial payment receivable activities during the six months ended June 30, 2023 (in thousands):

	Short-Term		Long-Term
Balance at January 1, 2023	$	2,366	$	63,683
Acquisition of royalty and commercial payment receivables:
Aptevo		—		9,650
LadRx		—		6,000
Receipt of royalty and commercial payments:
Affitech		(2,366)
Aptevo				(568)
Impairment of royalty and commercial payment receivables:
Bioasis				(1,575)
Reclassification to short-term royalty and commercial payment receivables:
Affitech		4,958		(4,958)
Balance at June 30, 2023	$	4,958	$	72,232